News
Novartis snaps up PI3Kα breast cancer drug in $3bn deal
Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
News
Kidney biotech R1's $78m debut, and other biofinancings
Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.
News
AZ piles pressure on MSD et al in gastric cancer
AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.
News
Denying prostate cancer screening 'no longer rational'
A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.
News
J&J says Inlexzo follow-up 'promising' in bladder cancer
Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
